173 related articles for article (PubMed ID: 19953878)
1. [Mycophenolate mofetil-based calcineurin inhibitor reduced immunosuppressive protocol for the improvement of renal dysfunction after liver transplantation].
Lai W; Lu SC; Wang ML; Zhang J; Wu JS; Dai J; Zeng DB; Xia RP; Li N
Zhonghua Yi Xue Za Zhi; 2009 Jun; 89(22):1529-32. PubMed ID: 19953878
[TBL] [Abstract][Full Text] [Related]
2. Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation.
Pageaux GP; Rostaing L; Calmus Y; Duvoux C; Vanlemmens C; Hardgwissen J; Bernard PH; Barbotte E; Vercambre L; Bismuth M; Puche P; Navarro F; Larrey D
Liver Transpl; 2006 Dec; 12(12):1755-60. PubMed ID: 17133564
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil.
Beckebaum S; Armstrong VW; Cicinnati VR; Streit F; Klein CG; Gerken G; Paul A; Oellerich M
Ther Drug Monit; 2009 Apr; 31(2):205-10. PubMed ID: 19307937
[TBL] [Abstract][Full Text] [Related]
4. Improvement of renal function after conversion to mycophenolate mofetil combined with low-level calcineurin inhibitor in liver transplant recipients with chronic renal dysfunction.
Ponton C; Vizcaíno L; Tomé S; Otero E; Molina E; Castroagudín JF; López-Lago A; Varo Pérez E
Transplant Proc; 2010 Mar; 42(2):656-9. PubMed ID: 20304216
[TBL] [Abstract][Full Text] [Related]
5. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
6. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure.
Groetzner J; Kaczmarek I; Schulz U; Stegemann E; Kaiser K; Wittwer T; Schirmer J; Voss M; Strauch J; Wahlers T; Sohn HY; Wagner F; Tenderich G; Stempfle HU; Mueller-Ehmsen J; Schmid C; Vogeser M; Koch KC; Reichenspurner H; Daebritz S; Meiser B; Reichart B;
Transplantation; 2009 Mar; 87(5):726-33. PubMed ID: 19295318
[TBL] [Abstract][Full Text] [Related]
7. Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation.
Raimondo ML; Dagher L; Papatheodoridis GV; Rolando N; Patch DW; Davidson BR; Rolles K; Burroughs AK
Transplantation; 2003 Jan; 75(2):186-90. PubMed ID: 12548120
[TBL] [Abstract][Full Text] [Related]
8. [Sirolimus use in heart transplantation recipients with chronic renal dysfunction].
Yin D; Huang J; Feng L; Liao ZK; Feng GX; Wang W; Song YH; Hu SS
Zhonghua Xin Xue Guan Bing Za Zhi; 2012 Feb; 40(2):136-40. PubMed ID: 22490714
[TBL] [Abstract][Full Text] [Related]
9. Prophylaxis of chronic kidney disease after liver transplantation--experience from west China.
Shao ZY; Yan LN; Wang WT; Li B; Wen TF; Yang JY; Xu MQ; Zhao JC; Wei YG
World J Gastroenterol; 2012 Mar; 18(9):991-8. PubMed ID: 22408361
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of mycophenolate mofetil in liver transplant recipients with calcineurin inhibitor-induced renal dysfunction.
Koch RO; Graziadei IW; Schulz F; Nachbaur K; Königsrainer A; Margreiter R; Vogel W
Transpl Int; 2004 Oct; 17(9):518-24. PubMed ID: 15365603
[TBL] [Abstract][Full Text] [Related]
11. Impact of combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy on renal function, cardiovascular risk factors, and graft function in liver transplant patients: preliminary results of an open prospective study.
Beckebaum S; Cicinnati VR; Klein CG; Brokalaki E; Yu Z; Malago M; Frilling A; Gerken G; Broelsch CE
Transplant Proc; 2004 Nov; 36(9):2671-4. PubMed ID: 15621120
[TBL] [Abstract][Full Text] [Related]
12. Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study.
Karie-Guigues S; Janus N; Saliba F; Dumortier J; Duvoux C; Calmus Y; Lorho R; Deray G; Launay-Vacher V; Pageaux GP
Liver Transpl; 2009 Sep; 15(9):1083-91. PubMed ID: 19718632
[TBL] [Abstract][Full Text] [Related]
13. Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results.
Reich DJ; Clavien PA; Hodge EE;
Transplantation; 2005 Jul; 80(1):18-25. PubMed ID: 16003228
[TBL] [Abstract][Full Text] [Related]
14. Long-term effects of calcineurin inhibitor conversion to mycophenolate mofetil on renal function after liver transplantation.
Créput C; Blandin F; Deroure B; Roche B; Saliba F; Charpentier B; Samuel D; Durrbach A
Liver Transpl; 2007 Jul; 13(7):1004-10. PubMed ID: 17600361
[TBL] [Abstract][Full Text] [Related]
15. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study.
Schlitt HJ; Barkmann A; Böker KH; Schmidt HH; Emmanouilidis N; Rosenau J; Bahr MJ; Tusch G; Manns MP; Nashan B; Klempnauer J
Lancet; 2001 Feb; 357(9256):587-91. PubMed ID: 11558484
[TBL] [Abstract][Full Text] [Related]
16. Conversion from calcineurin inhibitor to either mycophenolate mofetil or sirolimus improves renal function in liver transplant recipients with chronic kidney disease: results of a prospective randomized trial.
Herlenius G; Felldin M; Nordén G; Olausson M; Bäckman L; Gustafsson B; Friman S
Transplant Proc; 2010 Dec; 42(10):4441-8. PubMed ID: 21168715
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolate mofetil promotes prolonged improvement of renal dysfunction after pediatric liver transplantation: experience of a single center.
Tannuri U; Gibelli NE; Maksoud-Filho JG; Santos MM; Pinho-Apezzato ML; Velhote MC; Ayoub AA; Silva MM; Maksoud JG
Pediatr Transplant; 2007 Feb; 11(1):82-6. PubMed ID: 17239128
[TBL] [Abstract][Full Text] [Related]
18. Clinical trial: switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients--assessment of renal and allograft function, cardiovascular risk factors and immune monitoring.
Cicinnati VR; Yu Z; Klein CG; Sotiropoulos GC; Saner F; Malagó M; Frilling A; Gerken G; Broelsch CE; Beckebaum S
Aliment Pharmacol Ther; 2007 Nov; 26(9):1195-208. PubMed ID: 17944734
[TBL] [Abstract][Full Text] [Related]
19. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
Flechner SM; Kobashigawa J; Klintmalm G
Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
[TBL] [Abstract][Full Text] [Related]
20. Mycophenolate mofetil for renal dysfunction after pediatric liver transplantation.
Evans HM; McKiernan PJ; Kelly DA
Transplantation; 2005 Jun; 79(11):1575-80. PubMed ID: 15940048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
